Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i...
Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies...
David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO, Ma...
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with res...
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patie...
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a...
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common sto...
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat...
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies....
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.75 per share a year ago....
Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein Degrader of STAT6 Presented new case studi...